Literature DB >> 18726144

Immunotherapy of type 1 diabetes.

Li Li1, Zuoan Yi, Roland Tisch, Bo Wang.   

Abstract

Type 1 diabetes (T1D) is an autoimmune disease in which the insulin-producing beta cells are destroyed. Diabetic patients manage their hyperglycemia by daily insulin injections. However, insulin therapy is by no means a cure. Accordingly, a significant effort has been ongoing to develop immunotherapies that effectively prevent and/or treat T1D in the clinic. This review focuses on antigen- and antibody-based immunotherapies and discusses the respective strengths and weaknesses of these approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726144     DOI: 10.1007/s00005-008-0025-2

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  3 in total

1.  Cationic nanomicelles for delivery of plasmids encoding interleukin-4 and interleukin-10 for prevention of autoimmune diabetes in mice.

Authors:  Rhishikesh Mandke; Jagdish Singh
Journal:  Pharm Res       Date:  2011-11-11       Impact factor: 4.200

Review 2.  Teplizumab therapy for type 1 diabetes.

Authors:  Umesh B Masharani; Joseph Becker
Journal:  Expert Opin Biol Ther       Date:  2010-03       Impact factor: 4.388

3.  Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation.

Authors:  Preeti Chhabra; Kenneth L Brayman
Journal:  J Transplant       Date:  2011-10-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.